口服GLP-1“上桌”,电商成新战场?

CHC医疗传媒
Apr 29, 2025

这个4月,因为口服小分子,GLP-1赛道的战火,越燃越烈。4月14日辉瑞宣告其口服小分子GLP-1药物因安全性问题终止研发,引发行业一阵唏嘘。不料礼来立马抓着这一时机,宣布用于减重的口服小分子GLP-1RA药物orforglipronⅢ期临床研究成功,且预计今年底就会向全球监管机构提交上市申请。先抑后扬的一顿操作,礼来不仅获得一波股价暴涨,还直接将压力给到了诺和诺德。四天后,原本因为临床数据和产能...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10